Market Overview

UPDATE: Morgan Stanley Upgrades Medtronic Following Acquisition Of COV

Related MDT
5 Top Defense Technology Developments in 2014
Covidien Earnings Preview: Has Merger News Shaken Expectations?
FT: 25 More Firms May Seek Tax Breaks Overseas (Fox Business)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis upgraded the rating on Medtronic (NYSE: MDT) from Equal-Weight to Overweight, and named a $73.00 price target.

In the report, Morgan Stanley noted, “We are upgrading MDT to Overweight following its transformational acquisition of COV. The initial muted reaction (-1%) fails to appreciate greater financial upside through cost and tax synergies and peer leading capital deployment flexibility which should drive >10% returns.”

Medtronic closed on Monday at $60.03.

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Most Popular

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters